Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,478 | 388 | 1,041 |
| Samples | 1,164 | 299 | 846 |
| Peptides | 1,060 | 224 | 823 |
Function
RANBP2 · RAN binding protein 2
RAN is a small GTP-binding protein of the RAS superfamily that is associated with the nuclear membrane and is thought to control a variety of cellular functions through its interactions with other proteins. This gene encodes a very large RAN-binding protein that immunolocalizes to the nuclear pore complex. The protein is a giant scaffold and mosaic cyclophilin-related nucleoporin implicated in the Ran-GTPase cycle. The encoded protein directly interacts with the E2 enzyme UBC9 and strongly enhances SUMO1 transfer from UBC9 to the SUMO1 target SP100. These findings place sumoylation at the cytoplasmic filaments of the nuclear pore complex and suggest that, for some substrates, modification and nuclear import are linked events. This gene is partially duplicated in a gene cluster that lies in a hot spot for recombination on chromosome 2q. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000283195 | P49792 | 1,478 | 1,060 |
Gene Properties
Recurrent Mutations
All 1062 amino-acid changes on canonical ENST00000283195 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RANBP2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RANBP2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 19/42 45% | 66/612 11% |
| Oral Cavity Carcinoma | 7/54 13% | 0/0 0% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Acute Myeloid Leukemia | 7/90 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 14/57 25% | 38/810 5% |
| Melanoma | 20/210 10% | 93/1899 5% |
| Hodgkins Lymphoma | 5/16 31% | 2/122 2% |
| Non-Small Cell Lung Carcinoma | 36/304 12% | 49/1390 4% |
| Bladder Carcinoma | 4/58 7% | 44/956 5% |
| Cervical Carcinoma | 4/35 11% | 17/422 4% |
| Other Solid Cancers | 4/94 4% | 63/1515 4% |
| Colorectal Carcinoma | 39/143 27% | 100/3239 3% |
| Gastric Carcinoma | 12/74 16% | 62/1809 3% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Hepatocellular Carcinoma | 8/46 17% | 55/2210 2% |
| Burkitts Lymphoma | 3/32 9% | 3/196 2% |
| Germ Cell Tumour | 4/25 16% | 1/169 1% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Small Cell Lung Carcinoma | 1/9 11% | 17/752 2% |
| Meningioma | 0/3 0% | 5/252 2% |
| Other Sarcomas | 6/69 9% | 9/699 1% |
| Head and Neck Carcinoma | 7/85 8% | 24/1574 2% |
| Neuroendocrine Tumour | 7/154 5% | 6/577 1% |
| Retinoblastoma | 1/27 4% | 0/30 0% |
| Ovarian Carcinoma | 8/109 7% | 11/998 1% |
| Esophageal Squamous Cell Carcinoma | 7/51 14% | 37/2550 1% |
| Kidney Carcinoma | 4/85 5% | 27/1862 1% |
Mutation Distribution
Where RANBP2 is mutated · all tissues, split by cell line vs tissue
How many mutations in RANBP2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,478 mutations in RANBP2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|